Clindesse (Clindamycin Phosphate) Patent Expiration, LOE Window & CMS Spending
Clindesse (Clindamycin Phosphate) by Padagis Us: FDA Orange Book LOE 2026-12-02, 1 AB generics, $955K 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Padagis Us |
| FDA Application & Pathway | N050793 (NDA) |
| Exclusivity / Cliff Horizon | Immediate Cliff (2025-2027) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2026-12-02 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $955K |
| 2024 Medicare Part D Spend | $56K |
| 2024 Medicaid Spend | $898K |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |